These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 25157647

  • 1. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
    Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, Lombaard J, Manongi R, Kapiga S, Kashuba A, Van Damme L, FEM-PrEP Study Group.
    J Acquir Immune Defic Syndr; 2014 Jul 01; 66(3):324-31. PubMed ID: 25157647
    [Abstract] [Full Text] [Related]

  • 2. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
    Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C, Celum C.
    J Acquir Immune Defic Syndr; 2014 Jul 01; 66(3):340-8. PubMed ID: 24784763
    [Abstract] [Full Text] [Related]

  • 3. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM, Partners PrEP Study Team.
    Ann Intern Med; 2014 Jul 01; 161(1):11-9. PubMed ID: 24979446
    [Abstract] [Full Text] [Related]

  • 4. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
    Corneli A, Wang M, Agot K, Ahmed K, Lombaard J, Van Damme L, FEM-PrEP Study Group.
    J Acquir Immune Defic Syndr; 2014 Dec 15; 67(5):555-63. PubMed ID: 25393942
    [Abstract] [Full Text] [Related]

  • 5. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI, Uthman OA, Okoromah CA.
    Cochrane Database Syst Rev; 2012 Jul 11; 2012(7):CD007189. PubMed ID: 22786505
    [Abstract] [Full Text] [Related]

  • 6. Pregnancy and contraceptive use among women participating in the FEM-PrEP trial.
    Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, Van Damme L, Taylor D, FEM-PrEP Study Group.
    J Acquir Immune Defic Syndr; 2015 Feb 01; 68(2):196-203. PubMed ID: 25590272
    [Abstract] [Full Text] [Related]

  • 7. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR.
    J Acquir Immune Defic Syndr; 2013 Jul 01; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [Abstract] [Full Text] [Related]

  • 8. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, Parikh UM, Piper J, Mâsse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM, VOICE Study Team.
    N Engl J Med; 2015 Feb 05; 372(6):509-18. PubMed ID: 25651245
    [Abstract] [Full Text] [Related]

  • 9. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM, Partners PrEP Study Team.
    JAMA; 2015 Feb 05; 312(4):362-71. PubMed ID: 25038355
    [Abstract] [Full Text] [Related]

  • 10. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
    Agot K, Taylor D, Corneli AL, Wang M, Ambia J, Kashuba AD, Parker C, Lemons A, Malahleha M, Lombaard J, Van Damme L.
    AIDS Behav; 2015 May 05; 19(5):743-51. PubMed ID: 25100053
    [Abstract] [Full Text] [Related]

  • 11. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, Tumwesigye E, Psaros C, Safren SA, Ware NC, Thomas KK, Donnell D, Krows M, Kidoguchi L, Celum C, Bangsberg DR.
    PLoS Med; 2013 May 05; 10(9):e1001511. PubMed ID: 24058300
    [Abstract] [Full Text] [Related]

  • 12. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL.
    Drugs; 2013 Mar 05; 73(3):279-91. PubMed ID: 23444256
    [Abstract] [Full Text] [Related]

  • 13. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V, Fonsart J, Burlacu R, Gourmel B, Molina JM.
    Antimicrob Agents Chemother; 2011 Oct 05; 55(10):4905-7. PubMed ID: 21788466
    [Abstract] [Full Text] [Related]

  • 14. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
    Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, Bangsberg DR, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Kamali A, Priddy FH.
    PLoS One; 2013 Oct 05; 8(9):e74314. PubMed ID: 24086333
    [Abstract] [Full Text] [Related]

  • 15. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
    Celum C, Baeten JM.
    Curr Opin Infect Dis; 2012 Feb 05; 25(1):51-7. PubMed ID: 22156901
    [Abstract] [Full Text] [Related]

  • 16. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
    Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Priddy FH.
    PLoS One; 2012 Feb 05; 7(4):e33103. PubMed ID: 22511916
    [Abstract] [Full Text] [Related]

  • 17. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
    Mandala J, Nanda K, Wang M, De Baetselier I, Deese J, Lombaard J, Owino F, Malahleha M, Manongi R, Taylor D, Van Damme L.
    BMC Pharmacol Toxicol; 2014 Dec 24; 15():77. PubMed ID: 25539648
    [Abstract] [Full Text] [Related]

  • 18. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    JAMA Intern Med; 2015 Feb 24; 175(2):246-54. PubMed ID: 25531343
    [Abstract] [Full Text] [Related]

  • 19. Preexposure prophylaxis for HIV infection among African women.
    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D, FEM-PrEP Study Group.
    N Engl J Med; 2012 Aug 02; 367(5):411-22. PubMed ID: 22784040
    [Abstract] [Full Text] [Related]

  • 20. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
    Baeten JM, Haberer JE, Liu AY, Sista N.
    J Acquir Immune Defic Syndr; 2013 Jul 02; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.